GlassScriptPhysician profile
Richard N Lind
NPI 1437101045
$4,363.30
in general payments reported to CMS, 2019-2025
24 companies · $618 in 2025
The $618 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.05 · 2020: $15.43 · 2021: $1,036 · 2022: $955 · 2023: $872 · 2024: $805 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.89 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,145.71 | 2021-2025 | Kisqali, Piqray |
| Daiichi Sankyo INC. | $809.02 | 2021-2025 | Enhertu, Injectafer |
| Pfizer INC. | $347.53 | 2021-2025 | |
| Lilly USA, LLC | $345.57 | 2019-2024 | Verzenio |
| Merck Sharp & Dohme LLC | $239.39 | 2021-2025 | Keytruda, Lynparza |
| Astrazeneca Pharmaceuticals LP | $225.52 | 2021-2025 | Enhertu |
| Eisai INC. | $194.49 | 2020-2024 | |
| Gilead Sciences, INC. | $169.95 | 2021-2025 | Trodelvy |
| Seagen INC. | $135.25 | 2021-2023 | Tukysa |
| Organon LLC | $132.49 | 2021-2022 | |
| Tactile Systems Technology INC | $104.66 | 2021-2023 | Entre Plus, Flexitouch Plus |
| Puma Biotechnology, INC. | $100.82 | 2021-2024 | Nerlynx |
| Amgen INC. | $83.93 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $60.70 | 2021-2022 | |
| Abbvie INC. | $54.79 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $50.54 | 2021 | |
| Stemline Therapeutics INC. | $35.38 | 2023 | Orserdu |
| Tersera Therapeutics LLC | $22.19 | 2025 | Quzyttir |
| Bayer Healthcare Pharmaceuticals INC. | $20.56 | 2019 | |
| Tempus Ai, INC | $19.73 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $18.04 | 2025 | Exparel |
| Genentech USA, INC. | $18.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.30 | 2019 | |
| Genzyme Corporation | $12.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.